11 July 2023: Clinical Research
Corticosteroid-Associated Avascular Necrosis of the Femoral Head in Patients with Severe COVID-19: A Single-Center Study
Vensan Velchov 12ABCDE* , Pavel Georgiev 12ABCG , Stefan Tserovski 12DEFG , Tsvetan Tsenkov 12AEFG , Venelin Alexiev 12ACDEFDOI: 10.12659/MSM.940965
Med Sci Monit 2023; 29:e940965
Table 1 Summarized demographic and COVID-19-related patient data.
| Initials | Sex | Age | Therapy | COVID-19 | COVID-19 treatment duration | Days till AVN onset | D-dimer (μg/ml) | CRP (mg/L) | Orthopedic treatment |
|---|---|---|---|---|---|---|---|---|---|
| P.K.T. | M | 60 | 3×40 mg Methylprednisolone + 2×4 mg Dexamethasone | Severe | 7–30 days | 60 | 0.36 | 26 | THA |
| Y.G.A. | M | 59 | 2×40 mg Methylprednisolone | Severe | 7–30 days | 55 | 0.41 | 33 | THA |
| S.B.S. | M | 49 | 3×40 mg Methylprednisolone + 2×4 mg Dexamethasone | Severe | 7–30 days | 57 | 1.1 | 42 | THA + CDS |
| O.D.P. | F | 68 | 2×4 mg Dexamethasone | Moderate | 14 days | 66 | 27 | THA | |
| R.P.S. | M | 44 | 2×4 mg Dexamethasone | Moderate | 14 days | 46 | 25 | THA | |
| M.D.P. | M | 57 | 2×4 mg De×amathasone | Moderate | 21 days | 59 | 30 | THA | |
| A.H.D. | M | 68 | 2×40 mg Methylprednisolone + 2×4 mg Dexamethasone | Severe | 21 days | 65 | 0.29 | 25 | THA |
| W.G.P. | M | 49 | 2× 4 mg Dexamethasone | Moderate | 21 days | 58 | 24 | THA | |
| L.D.K. | M | 61 | 2×4 mg Dexamethasone | Severe | 21 days | 65 | 0.32 | 24 | THA |
| D.D.C. | M | 57 | 2×4 mg Dexamethasone | Moderate | 21 days | 59 | 33 | THA | |
| A.H.K. | F | 51 | 2×40 mg Methylprednisolone + 2×4 mg Dexamethasone | Severe | 14–30 days | 48 | 0.35 | 34 | THA |
| L.H.G. | F | 67 | 2×40 mg Methylprednisolone + 2×4 mg Dexamethasone | Severe | 14–30 days | 69 | 0.37 | 26 | THA |
| P.D.T. | M | 58 | 2×4 mg Dexamethasone | Severe | 21 days | 60 | 0.3 | 24 | CDS |
| M.G.H. | M | 39 | 3×40 mg Methylprednisolone + 2×4 mg Dexamethasone | Severe | 14–30 days | 47 | 0.4 | 30 | THA |
| L.K.Y. | F | 68 | 2×40 mg Methylprednisolone+ 2×4 mg Dexamethasone | Severe | 7–30 days | 65 | 0.44 | 31 | THA |
| P.D.M. | M | 49 | 3×40 mg Methylprednisolone +2×4 mg Dexamethasone | Severe | 14–30 days | 49 | 0.34 | 34 | THA + CDS |
| S.D.B. | M | 53 | 2×40 mg Methylprednisolone | Severe | 14–30 days | 60 | 0.41 | 36 | THA |
| G.I.B. | F | 61 | 2×4 mg Dexamethasone | Moderate | 21 days | 57 | 30 | THA | |
| S.I.L. | F | 43 | 2×40 mg Methylprednisolone | Severe | 7–30 days | 49 | 0.32 | 38 | THA |
| Y.Y.G. | M | 49 | 2×40 mg Methylprednisolone | Severe | 14–30 days | 51 | 0.44 | 36 | THA + CDS |
| P.G.H. | M | 57 | 2×40 mg Methylprednisolone | Severe | 14–30 days | 62 | 0.29 | 32 | THA |
| S.I.S. | M | 60 | 2×4 mg Dexamethasone | Moderate | 21 days | 55 | 35 | THA | |
| I.G.I. | F | 51 | 2×4 mg Dexamethasone | Moderate | 21 days | 50 | 24 | THA | |
| P.Y.P. | M | 57 | 2×40 mg Methylprednisolone | Severe | 14–30 days | 61 | 0.45 | 34 | THA + CDS |